Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
52 hedge funds and large institutions have $39.5M invested in Cidara Therapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 8 closing their positions.
82% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 11
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 50 → 52 (+2)
0.43% more ownership
Funds ownership: 1.9% → 2.33% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $42.1M → $39.5M (-$2.66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$8.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.54M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.24M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.38M |
| 5 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$4.49M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.33M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$827K |
| 4 |
Millennium Management
New York
|
-$362K |
| 5 |
E
Ergoteles
New York
|
-$359K |
CDTX Hedge Fund Activity: Q4 2021 in Review
52 of the 6,517 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2021, worth a combined $39.5M — down 6.3% from $42.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CDTX positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 11 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $8.2M. The largest seller was Omega Fund Management, exiting entirely with an estimated $4.49M sold.
- 52 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2021, up from 50 in Q3 2021.
- Funds reported $39.5M of Cidara Therapeutics stock for Q4 2021, down 6.3% quarter-over-quarter.
- 11 funds opened new Cidara Therapeutics positions in Q4 2021 and 8 closed out, a net change of +3 holders.
- The largest Cidara Therapeutics buyer in Q4 2021 was Nantahala Capital Management, an estimated $8.2M added.
- The largest Cidara Therapeutics seller in Q4 2021 was Omega Fund Management, an estimated $4.49M sold.
Based on aggregated 13F filings for Q4 2021.